by John Conrad | Dec 12, 2024 | Member News, NewsBrief
In a significant move addressing one of healthcare’s most pressing challenges, Meitheal Pharmaceuticals has secured exclusive U.S. commercial rights to XENLETA® (lefamulin acetate). The timing couldn’t be more critical: between now and 2050, antibiotic...
